Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents

Novo Nordisk A/S1,667 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes and other adverse events, and to evaluate efficacy while using insulin under normal clinical practice conditions. The switch from OAD treatment to insulin therapy will be determined by physician.

Study Type

OBSERVATIONAL

Enrollment

1,667

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

soluble human insulinDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

biphasic human insulinDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

insulin NPHDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes for at least 12 months and currently receiving oral anti-diabetic (OAD) treatment, whether single or combination, for at least 3 months before this study * Insulin naive * Poor glycaemic control on OADs and decided by the physician to start insulin therapy Exclusion Criteria: * Type 1 diabetes patients * Patients who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit * Patients with a hypersensitivity to insulin or to any of the excipients * Patient groups not approved in the product label

Locations (1)

Novo Nordisk Investigational Site

Jakarta, Indonesia